Literature DB >> 9891544

Clinical toxicity of cryopreserved circulating progenitor cells infusion.

A Zambelli1, G Poggi, G Da Prada, P Pedrazzoli, A Cuomo, D Miotti, C Perotti, P Preti, G Robustelli della Cuna.   

Abstract

BACKGROUND: We evaluated the infusion-related toxicity of cryopreserved autologous circulating progenitor cells transplanted in 22 patients receiving high dose chemotherapy and stem cells transplantation for malignancy.
MATERIALS AND METHODS: Progenitor cells were collected following mobilization with chemotherapy plus filgrastim and stored in liquid nitrogen in the presence of 10% dimethylsulfoxide (DMSO). Before infusion of the graft, patients were medicated with mannitol, hydrocortisone and clorphenamine. The amount of DMSO infused as well as the number of dead and damaged cells were evaluated as possible cause of toxicity.
RESULTS: Eleven patients (50%) experienced symptoms related to graft infusion, nausea and vomiting being the most common adverse events. Hypotension was documented in 3 patients (one of them developing transient bradycardia resolved with atropin administration) and one had hypertension with tachycardia. Other observed side effects were: chest tightness (2 pts), fever and chills (3 pts), associated with abdominal cramps (2 pts). 7 out of 8 (88%) patients infused with greater than 30 mL volume of DMSO experienced side-effects, the grade of toxicity being significantly less in those receiving lower amount (< 30 mL) of DMSO. Two out of 4 pts who received the highest number of dead cells (> 10 x 10(9)) developed toxicity.
CONCLUSIONS: In our experience the infusion of cryopreserved peripheral blood progenitors caused minor to moderate toxicity in most cases and, when present, side effects were observed only during infusion. The amount of DMSO present in the graft is related to the grade of toxicity.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9891544

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  22 in total

Review 1.  Cryopreservation of hematopoietic stem cells.

Authors:  David Berz; Elise M McCormack; Eric S Winer; Gerald A Colvin; Peter J Quesenberry
Journal:  Am J Hematol       Date:  2007-06       Impact factor: 10.047

2.  Respiratory depression and somnolence in children receiving dimethylsulfoxide and morphine during hematopoietic stem cells transplantation.

Authors:  Désirée Caselli; Veronica Tintori; Andrea Messeri; Stefano Frenos; Franco Bambi; Maurizio Aricò
Journal:  Haematologica       Date:  2008-11-10       Impact factor: 9.941

3.  Inducing Heat Shock Proteins Enhances the Stemness of Frozen-Thawed Adipose Tissue-Derived Stem Cells.

Authors:  Shahensha Shaik; Daniel Hayes; Jeffrey Gimble; Ram Devireddy
Journal:  Stem Cells Dev       Date:  2017-02-16       Impact factor: 3.272

4.  Adverse reactions during stem cell infusion in children treated with autologous and allogeneic stem cell transplantation.

Authors:  T H Truong; R Moorjani; D Dewey; G M T Guilcher; N L Prokopishyn; V A Lewis
Journal:  Bone Marrow Transplant       Date:  2016-01-11       Impact factor: 5.483

5.  Limiting the daily total nucleated cell dose of cryopreserved peripheral blood stem cell products for autologous transplantation improves infusion-related safety with no adverse impact on hematopoietic engraftment.

Authors:  Nandita Khera; Jack Jinneman; Barry E Storer; Shelly Heimfeld; Megan M O'Meara; Thomas R Chauncey; Stephanie J Lee; Michael Linenberger
Journal:  Biol Blood Marrow Transplant       Date:  2011-06-15       Impact factor: 5.742

6.  Stability of cryopreserved white blood cells (WBCs) prepared for donor WBC infusions.

Authors:  David F Stroncek; Lu Xing; Quyen Chau; Nausheen Zia; Alyce McKelvy; Leigh Pracht; Marianna Sabatino; Ping Jin
Journal:  Transfusion       Date:  2011-06-09       Impact factor: 3.157

Review 7.  Hematopoietic SCT with cryopreserved grafts: adverse reactions after transplantation and cryoprotectant removal before infusion.

Authors:  Z Shu; S Heimfeld; D Gao
Journal:  Bone Marrow Transplant       Date:  2013-09-30       Impact factor: 5.483

8.  5% dimethyl sulfoxide (DMSO) and pentastarch improves cryopreservation of cord blood cells over 10% DMSO.

Authors:  Jun Hayakawa; Elizabeth G Joyal; Jean F Gildner; Kareem N Washington; Oswald A Phang; Naoya Uchida; Matthew M Hsieh; John F Tisdale
Journal:  Transfusion       Date:  2010-10-04       Impact factor: 3.157

9.  Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90.

Authors:  Jens R Sydor; Emmanuel Normant; Christine S Pien; James R Porter; Jie Ge; Louis Grenier; Roger H Pak; Janid A Ali; Marlene S Dembski; Jebecka Hudak; Jon Patterson; Courtney Penders; Melissa Pink; Margaret A Read; Jim Sang; Caroline Woodward; Yilong Zhang; David S Grayzel; Jim Wright; John A Barrett; Vito J Palombella; Julian Adams; Jeffrey K Tong
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-07       Impact factor: 11.205

10.  The heat shock protein 90 inhibitor IPI-504 induces apoptosis of AKT-dependent diffuse large B-cell lymphomas.

Authors:  Jeremy S Abramson; Wen Chen; Przemyslaw Juszczynski; Hidenobu Takahashi; Donna Neuberg; Jeffery L Kutok; Kunihiko Takeyama; Margaret A Shipp
Journal:  Br J Haematol       Date:  2008-11-13       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.